Nafamostat

Nafamostat
Nafamostat
Systematic (IUPAC) name
6-[amino(imino)methyl]-2-naphthyl 4-{[amino(imino)methyl]amino}benzoate
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat.  ?
Legal status ℞ Prescription only
Routes IV
Identifiers
CAS number 81525-10-2
ATC code None
PubChem CID 4413
UNII Y25LQ0H97D YesY
Chemical data
Formula C19H17N5O2 
Mol. mass 347.37 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

Nafamostat (INN) is an anticoagulant.


v · d · eAntithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)
Antiplatelet drugs
Thromboxane inhibitors
thromboxane synthase inhibitors (Dipyridamole, Picotamide) • receptor antagonist (Terutroban†)
Other
Anticoagulants
Vitamin K antagonists
(inhibit II, VII, IX, X)
Factor Xa inhibitors
(with some II inhibition)
xabans (Apixaban, Betrixaban, Edoxaban, Otamixaban, Rivaroxaban)

bivalent: Hirudin (Bivalirudin, Lepirudin, Desirudin)

univalent: Argatroban • Dabigatran • Melagatran‡ • Ximelagatran‡
Other
Thrombolytic drugs/
fibrinolytics
Non-medicinal
Citrate • EDTA • Oxalate
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: MYL

cell/phys (coag, heme, immu, gran), csfs

rbmg/mogr/tumr/hist, sysi/epon, btst

drug (B1/2/3+5+6), btst, trns


Stub icon This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.